Evidence that IL-6-type cytokine signaling in cardiomyocytes is inhibited by oxidative stress: Parthenolide targets JAK1 activation by generating ROS

Journal of Cellular Physiology

Volumn 212, Issue 2, 2007, Pages 424-431

  Kurdi, Mazen ^a   Booz, George W ^a,b  

^a Texas A and M University   (United States)

^b TEXAS A M COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CYTOKINE; GLYCOPROTEIN GP 130; INTERLEUKIN 6; JANUS KINASE 1; PARTHENOLIDE; REACTIVE OXYGEN METABOLITE; RECEPTOR SUBUNIT; STAT3 PROTEIN;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME SUBUNIT; HEART MUSCLE CELL; NEWBORN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RAT; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

ACETYLCYSTEINE; ANIMALS; ANIMALS, NEWBORN; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; CYTOKINE RECEPTOR GP130; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HEART VENTRICLES; INTERLEUKIN-6; JANUS KINASE 1; JANUS KINASE 2; LEUKEMIA INHIBITORY FACTOR; LEUKEMIA INHIBITORY FACTOR RECEPTOR ALPHA SUBUNIT; MYOCYTES, CARDIAC; OXIDATIVE STRESS; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; SESQUITERPENES; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 34347374690     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21033     Document Type: Article

References (29)

1. Aruoma OI, Halliwell B, Hoey BM, Butler J. 1989. The antioxidant action of N-acetylcysteine: Its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med 6:593-597.
2. Booz GW, Day JN, Baker KM. 2002a. Interplay between the cardiac renin angiotensin system and JAK-STAT signaling: Role in cardiac hypertrophy, ischemia/reperfusion dysfunction, and heart failure. J Mol Cell Cardiol 34:1443-1453.
3. Booz GW, Day JN, Speth R, Baker KM. 2002b. Cytokine G-protein signaling crosstalk in cardiomyocytes: Attenuation of Jak-STAT activation by endothelin-1. Mol Cell Biochem 240:39-46.
4. Booz GW, Day JN, Baker KM. 2003. Angiotensin II effects on STAT3 phosphorylation in cardiomyocytes: Evidence for Erk-dependent Tyr705 dephosphorylation. Basic Res Cardiol 98:33-38.
5. Curry EAIII, Murry DJ, Yoder C, Fife K, Armstrong V, Nakshatri H, O'Connell M, Sweeney CJ. 2004. Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer. Invest New Drugs 22:299-305.
6. Duhé RJ, Evans GA, Erwin RA, Kirken RA, Cox GW, Farrar WL. 1998. Nitric oxide and thiol redox regulation of Janus kinase activity. Proc Natl Acad Sci USA 95:126-131.
7. Ernst M, Jenkins BJ. 2004. Acquiring signalling specificity from the cytokine receptor gp130. Trends Genet 20:23-32.
8. Gamero AM, Young HA, Wiltrout RH. 2004. Inactivation of Stat3 in tumor cells: Releasing a brake on immune responses against cancer? Cancer Cell 5:111-112.
9. Garcia-Pineres AJ, Castro V, Mora G, Schmidt TJ, Strunck E, Pahl HL, Merfort I. 2001. Cysteine 38 in p65/NF-κB plays a crucial role in DNA binding inhibition by sesquiterpene lactones. J Biol Chem 276:39713-39720.
10. Giese B, Au-Yeung CK, Herrmann A, Diefenbach S, Haan C, Kuster A, Wortmann SB, Roderburg C, Heinrich PC, Behrmann I, Muller-Newen G. 2003. Long term association of the cytokine receptor gp130 and the Janus kinase Jak1 revealed by FRAP analysis. J Biol Chem 278:39205-39213.
11. Hall IH, Lee KH, Starnes CO, Sumida Y, Wu RY, Waddell TG, Cochran JW, Gerhart KG. 1979. Anti-inflammatory activity of sesquiterpene lactones and related compounds. J Pharm Sci 68:537-542.
12. Hehner SP, Hofmann TG, Droge W, Schmitz ML. 1999. The antiinflammatory sesquiterpene lactone parthenolide inhibits NF-κB by targeting the IκB kinase complex. J Immunol 163:5617-5623.
13. Hwang D, Fischer NH, Jang BC, Tak H, Kim JK, Lee W. 1996. Inhibition of the expression of inducible cyclooxygenase and proinflammatory cytokines by sesquiterpene lactones in macrophages correlates with the inhibition of MAP kinases. Biochem Biophys Res Commun 226:810-818.
14. Kamimura D, Ishihara K, Hirano T. 2003. IL-6 signal transduction and its physiological roles: The signal orchestration model. Rev Physiol Biochem Pharmacol 149:1-38.
15. 2 regulates cardiac myocyte phenotype via concentration-dependent activation of distinct kinase pathways. J Mol Cell Cardiol 35:615-621.
16. Legendre F, Dudhia J, Pujol JP, Bogdanowicz P. 2003. JAK/STAT but not ERK1/ERK2 pathway mediates interleukin (IL)-6/soluble IL-6R down-regulation of Type II collagen, aggrecan core, and link protein transcription in articular chondrocytes. Association with a down-regulation of SOX9 expression. J Biol Chem 278: 2903-2912.
17. Lornejad-Schafer M, Albrecht U, Poppek D, Gehrmann T, Grune T, Bode JG, Haussinger D, Schliess F. 2005. Osmotic regulation of STAT3 stability in H4IIE rat hepatoma cells. FEBS Lett 579:5791-5797.
18. Mitsuhashi S, Shima H, Tanuma N, Sasa S, Onoe K, Ubukata M, Kikuchi K. 2005. Protein phosphatase type 2A. PP2A, is involved in degradation of gp130. Mol Cell Biochem 269:183-187.
19. Nakshatri H, Rice SE, Bhat-Nakshatri P. 2004. Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase. Oncogene 23:7330-7344.
20. Pimentel DR, Amin JK, Xiao L, Miller T, Viereck J, Oliver-Krasinski J, Baliga R, Wang J, Siwik DA, Singh K, Pagano P, Colucci WS, Sawyer DB. 2001. Reactive oxygen species mediate amplitude-dependent hypertrophic and apoptotic responses to mechanical stretch in cardiac myocytes. Circ Res 89:453-460.
21. Radtke S, Haan S, Jorissen A, Hermanns HM, Diefenbach S, Smyczek T, Schmitz-Vandeleur H, Heinrich PC, Behrmann I, Haan C. 2005. The Jak1 SH2 domain does not fulfill a classical SH2 function in Jak/STAT signaling but plays a structural role for receptor interaction and up-regulation of receptor surface expression. J Biol Chem 280:25760-25768.
22. Rodig SJ, Meraz MA, White JM, Lampe PA, Riley JK, Arthur CD, King KL, Sheehan K, Yin L, Pennica D, Johnson EM, Jr., Schreiber RD. 1998. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 93:373-383.
23. Sheehan M, Wong HR, Hake PW, Malhotra V, O'Connor M, Zingarelli B. 2002. Parthenolide. an inhibitor of the nuclear factor-κB pathway, ameliorates cardiovascular derangement and outcome in endotoxic shock in rodents. Mol Pharmacol 61:953-963.
24. Sobota R, Szwed M, Kasza A, Bugno M, Kordula T. 2000. Parthenolide inhibits activation of signal transducers and activators of transcription (STATs) induced by cytokines of the IL-6 family. Biochem Biophys Res Commun 267:329-333.
25. Timmermann A, Kuster A, Kurth I, Heinrich PC, Muller-Newen G. 2002. A functional role of the membrane-proximal extracellular domains of the signal transducer gp130 in heterodimerization with the leukemia inhibitory factor receptor. Eur J Biochem 269:2716-2726.
26. Weber JT, O'Connor MF, Hayataka K, Colson N, Medora R, Russo EB, Parker KK. 1997. Activity of parthenolide at 5HT2A receptors. J Nat Prod 60:651-653.
27. Wen J, You KR, Lee SY, Song CH, Kim DG. 2002. Oxidative stress-mediated apoptosis. The anticancer effect of the sesquiterpene lactone parthenolide. J Biol Chem 277:38954-38964.
28. Won YK, Ong CN, Shi X, Shen HM. 2004. Chemopreventive activity of parthenolide against UVB-induced skin cancer and its mechanisms. Carcinogenesis 25:1449-1458.
29. Zingarelli B, Hake PW, Denenberg A, Wong HR. 2002. Sesquiterpene lactone parthenolide, an inhibitor of IκB kinase complex and nuclear factor-κB. exerts beneficial effects in myocardial reperfusion injury. Shock 17:127-134.